| Expression pattern: |
UP |
| Associated gene: |
BMI1 |
| Associated microRNA: |
miR-802 |
| Biological function: |
Promotes cisplatin (DDP) resistance; promotes cell viability/proliferation and inhibits apoptosis under DDP treatment in gastric cancer cells. |
| Molecular mechanism: |
Acts as a miRNA sponge (ceRNA) for miR-802 to indirectly increase BMI1 expression, thereby enhancing cisplatin resistance. |
| Biological pathway or process: |
chemoresistance (promotes); apoptosis (inhibits); proliferation (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; Clinical Sample Validation |
| Clinical significance: |
CircDONSON is elevated in DDP-resistant GC tissues; circDONSON may be a therapeutic target to overcome chemoresistance in gastric cancer patients. |
| Description: |
circDONSON is up-regulated in gastric cancer, especially in cisplatin (DDP)-resistant tissues/cells. It promotes cisplatin resistance by sponging miR-802 and thereby increasing BMI1 expression, leading to enhanced proliferation/viability and reduced apoptosis under DDP treatment. |
| Confidence score: |
0.7412 |